A detailed history of Paloma Partners Management CO transactions in Halozyme Therapeutics, Inc. stock. As of the latest transaction made, Paloma Partners Management CO holds 2,315 shares of HALO stock, worth $124,917. This represents 0.0% of its overall portfolio holdings.

Number of Shares
2,315
Previous 9,900 76.62%
Holding current value
$124,917
Previous $518,000 74.52%
% of portfolio
0.0%
Previous 0.02%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$51.3 - $64.42 $389,110 - $488,625
-7,585 Reduced 76.62%
2,315 $132,000
Q2 2024

Aug 14, 2024

BUY
$37.81 - $52.4 $374,319 - $518,760
9,900 New
9,900 $518,000
Q2 2021

Aug 16, 2021

SELL
$38.84 - $51.31 $420,986 - $556,149
-10,839 Closed
0 $0
Q1 2021

May 17, 2021

BUY
$39.51 - $51.45 $428,248 - $557,666
10,839 New
10,839 $451,000
Q4 2020

Feb 16, 2021

SELL
$25.81 - $43.62 $597,733 - $1.01 Million
-23,159 Closed
0 $0
Q3 2020

Nov 16, 2020

BUY
$25.74 - $29.63 $596,112 - $686,201
23,159 New
23,159 $609,000
Q1 2020

May 15, 2020

SELL
$13.9 - $21.83 $357,813 - $561,947
-25,742 Closed
0 $0
Q4 2019

Feb 14, 2020

BUY
$14.93 - $19.53 $384,328 - $502,741
25,742 New
25,742 $456,000
Q1 2019

May 15, 2019

SELL
$13.94 - $17.58 $143,261 - $180,669
-10,277 Closed
0 $0
Q4 2018

Feb 14, 2019

BUY
$13.33 - $18.66 $136,992 - $191,768
10,277 New
10,277 $150,000
Q2 2018

Aug 14, 2018

SELL
$16.87 - $20.3 $761,343 - $916,139
-45,130 Closed
0 $0
Q1 2018

May 15, 2018

BUY
$17.06 - $21.2 $769,917 - $956,756
45,130 New
45,130 $885,000

Others Institutions Holding HALO

About HALOZYME THERAPEUTICS, INC.


  • Ticker HALO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 139,288,992
  • Market Cap $7.52B
  • Description
  • Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable...
More about HALO
Track This Portfolio

Track Paloma Partners Management CO Portfolio

Follow Paloma Partners Management CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Paloma Partners Management CO, based on Form 13F filings with the SEC.

News

Stay updated on Paloma Partners Management CO with notifications on news.